Conditions masquerading as infantile haemangioma: Part 2

Frieden, Ilona J.; Rogers, Maureen; Garzon, María C.

doi:10.1111/j.1440-0960.2009.00529_1.x

Cited by 50 publications

(38 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infantile fibrosarcoma (IFS) is the most common non-rhabdomyosarcoma soft tissue tumor with an incidence of 24.5 % of all soft tissue sarcomas seen in the first year of life [2]. It can be present at birth or can develop during the first 5 years, particularly in infants and toddlers younger than 2 years; 80 % of cases are diagnosed during the first year of life [3–5]. IFS most commonly presents as a non-tender, poorly circumscribed mass varying in size and consistency [6, 7].…”

Section: Introductionmentioning

confidence: 99%

Clinical management of infantile fibrosarcoma: a retrospective single-institution review

et al. 2013

View full text Add to dashboard Cite

Background Infantile fibrosarcoma (IFS) is an uncommon soft-tissue sarcoma. Here we review our experience treating this tumor. Patients and methods We retrospectively reviewed records of patients with IFS treated at St. Jude Children’s Research Hospital between 1980 and 2009. Results We identified 15 patients, 8 girls and 7 boys; 13 white and 2 black. Median age at diagnosis was 3 months. Primary sites included the leg (n = 3), chest wall (n = 2), foot (n = 2), and one each in the tongue, occipital region, axilla, parascapular region, arm, forearm, retroperitoneum, and thigh. All patients underwent resection; 11 upfront surgery, and 4 delayed. Complications included loss of the posterior tibial nerve and artery, axillary vein, biceps, pectoralis major, gallbladder, and transverse/sigmoid sinus. Eight received chemotherapy and three radiotherapy. Seven experienced local recurrence and three lung metastasis. Median follow-up was 65 months. At the time of the review, 12 patients were alive and 3 had died. All deaths were in patients older than 1 year at diagnosis with an axial primary site. Conclusions Non-mutilating surgery should be the primary treatment for IFS. Neoadjuvant chemotherapy is indicated when upfront resection is unfeasible. Patients with positive surgical margins should receive adjuvant chemotherapy. Radiotherapy is indicated for axial primary sites where complete resection is impossible.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical management of infantile fibrosarcoma: a retrospective single-institution review

et al. 2013

View full text Add to dashboard Cite

show abstract

“…IH are unique vascular tumours which differ in both clinical behaviour and immunohistochemical markers from other vascular tumours and malformations with which they are sometimes confused 3. IH are typically absent or present as a precursor lesion at birth, becoming noticeable in the first few weeks of life, and often proliferate rapidly during the first few weeks to months of life.…”

Section: Introductionmentioning

confidence: 99%

Management of difficult infantile haemangiomas: Table 1

Maguiness

Frieden

2012

Arch Dis Child

Self Cite

View full text Add to dashboard Cite

Infantile haemangiomas are common vascular tumours of infancy. They typically present shortly after birth, undergo a period of rapid proliferation, and then slowly involute over many years. Although most patients require no intervention, appropriate investigation and treatment may be necessary in a minority of cases. Identifying which patients require further investigation or intervention can be difficult due to the heterogeneity of clinical presentation. This is compounded by a lack of rigorous randomised controlled trials on haemangioma management. Therefore, the rationale for treatment is not always straightforward. Haemangiomas occur anywhere on the body, have superficial, deep or mixed morphology, and depending on anatomic location, size and subtype, can be associated with underlying structural anomalies and many other potential complications. Generally, the management of difficult haemangiomas is best approached on a case-by-case basis. Over the last few years, there have been several advances in our understanding of haemangiomas, together with some exciting new therapeutic options. In the following review, the authors discuss the various possible complications of infantile haemangiomas, the rationale for treatment and appropriate possible interventions.

show abstract

“…[5] In our case, the anatomic location and much higher frequency of IH in the neonatal population made IH the suspected diagnosis, but as Frieden et al . [5] suggested, the congenital nature of the lesion and the presence of scarring and skin contracture are clinical clues suggestive of something other than IH. IH typically appear between 1 and 4 weeks of age and demonstrates rapid growth over a few months, with involution occurring over several years.…”

mentioning

confidence: 58%

“…It is crucial to exclude other processes such as IM, fibrosarcoma, rhabdomyosarcoma and kaposiform hemangioendothelioma, which have different treatments and prognosis. [12345]…”

mentioning

confidence: 99%